Peijia Medical
Xin Shane Zhang is a seasoned professional in the medical technology and pharmaceuticals industry, currently serving as Founding Partner and President of Suzhou Interventional Medtech Institute since January 2022, and as Vice President of Business Development at Peijia Medical (Suzhou) Co., Ltd since March 2021. Zhang has extensive experience, having held roles such as General Manager of Medical Devices at Shenzhen Salubris Pharmaceuticals and Marketing Director at Smith & Nephew, among others. Zhang’s career highlights include significant contributions to product launches, regulatory affairs, and innovative device development while at Medtronic, where achievements included leading the recall of the Sprint Fidelis product and earning multiple awards for excellence and creativity. Academic credentials include an MBA from The Wharton School, a PhD in Biomedical Engineering from the University of Minnesota, and a Master’s degree in Biomedical Engineering from Zhejiang University.
This person is not in any teams
Peijia Medical
Peijia Medical (HKEX: 9996), headquartered in Suzhou, China, is a leading medical device company dedicated to interventional solutions for structural heart and neurovascular diseases in China and globally. Established in 2012, Peijia Medical has long been committed to provide safe, effective and affordable solutions to improve patients’ quality of life through continuous innovations. We offer a complete portfolio of therapies to address aortic valve (Taurus Series), mitral valve and tricuspid valve replacement and repair, as well as neurovascular diseases related to brain ischemia and hemorrhage. 沛嘉医疗（港交所代码：9996）总部位于中国苏州，为中国乃至全球的结构性心脏病和脑血管介入领域提供解决方案。 沛嘉医疗成立于2012年，长期以来致力于通过持续的创新，为患者提供安全、有效、低成本的医疗方案，提升患者生活质量。我们拥有完整的产品治疗管线，包括主动脉瓣（Taurus系列产品）、二尖瓣和三尖瓣的置换和修复产品，以及与缺血性和出血性相关的脑血管疾病介入产品。